Logo image of OCI.AS

OCI NV (OCI.AS) Stock Fundamental Analysis

AMS:OCI - Euronext Amsterdam - NL0010558797 - Common Stock - Currency: EUR

10.9  0 (0%)

Fundamental Rating

2

Taking everything into account, OCI scores 2 out of 10 in our fundamental rating. OCI was compared to 60 industry peers in the Chemicals industry. OCI may be in some trouble as it scores bad on both profitability and health. OCI has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year OCI has reported negative net income.
OCI had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: OCI reported negative net income in multiple years.
Each year in the past 5 years OCI had a positive operating cash flow.
OCI.AS Yearly Net Income VS EBIT VS OCF VS FCFOCI.AS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1B 2B 3B

1.2 Ratios

OCI has a Return On Assets of -5.57%. This is in the lower half of the industry: OCI underperforms 71.93% of its industry peers.
The Return On Equity of OCI (-54.32%) is worse than 87.72% of its industry peers.
Industry RankSector Rank
ROA -5.57%
ROE -54.32%
ROIC N/A
ROA(3y)4.7%
ROA(5y)1.72%
ROE(3y)13.16%
ROE(5y)-0.18%
ROIC(3y)N/A
ROIC(5y)N/A
OCI.AS Yearly ROA, ROE, ROICOCI.AS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40 -40

1.3 Margins

Looking at the Gross Margin, with a value of 2.10%, OCI is doing worse than 85.96% of the companies in the same industry.
OCI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 2.1%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OCI.AS Yearly Profit, Operating, Gross MarginsOCI.AS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10 -10 20 30

More info and screens

3

2. Health

2.1 Basic Checks

OCI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for OCI remains at a similar level compared to 1 year ago.
OCI has more shares outstanding than it did 5 years ago.
The debt/assets ratio for OCI has been reduced compared to a year ago.
OCI.AS Yearly Shares OutstandingOCI.AS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M
OCI.AS Yearly Total Debt VS Total AssetsOCI.AS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2B 4B 6B 8B

2.2 Solvency

Based on the Altman-Z score of 0.20, we must say that OCI is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of 0.20, OCI is not doing good in the industry: 82.46% of the companies in the same industry are doing better.
OCI has a debt to FCF ratio of 44.52. This is a negative value and a sign of low solvency as OCI would need 44.52 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 44.52, OCI is in line with its industry, outperforming 42.11% of the companies in the same industry.
A Debt/Equity ratio of 2.03 is on the high side and indicates that OCI has dependencies on debt financing.
OCI has a Debt to Equity ratio of 2.03. This is amonst the worse of the industry: OCI underperforms 94.74% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.03
Debt/FCF 44.53
Altman-Z 0.2
ROIC/WACCN/A
WACC5.65%
OCI.AS Yearly LT Debt VS Equity VS FCFOCI.AS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1B 2B 3B 4B

2.3 Liquidity

A Current Ratio of 1.39 indicates that OCI should not have too much problems paying its short term obligations.
The Current ratio of OCI (1.39) is worse than 75.44% of its industry peers.
OCI has a Quick Ratio of 1.37. This is a normal value and indicates that OCI is financially healthy and should not expect problems in meeting its short term obligations.
OCI has a Quick ratio of 1.37. This is in the better half of the industry: OCI outperforms 64.91% of its industry peers.
Industry RankSector Rank
Current Ratio 1.39
Quick Ratio 1.37
OCI.AS Yearly Current Assets VS Current LiabilitesOCI.AS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2B 4B 6B

More info and screens

1

3. Growth

3.1 Past

OCI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -123.19%.
Looking at the last year, OCI shows a very negative growth in Revenue. The Revenue has decreased by -63.19% in the last year.
OCI shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -9.61% yearly.
EPS 1Y (TTM)-123.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%164.52%
Revenue 1Y (TTM)-63.19%
Revenue growth 3Y-17.33%
Revenue growth 5Y-9.61%
Sales Q2Q%-11.72%

3.2 Future

The Earnings Per Share is expected to grow by 26.31% on average over the next years. This is a very strong growth
Based on estimates for the next years, OCI will show a very negative growth in Revenue. The Revenue will decrease by -15.65% on average per year.
EPS Next Y91.45%
EPS Next 2Y60.43%
EPS Next 3Y42.31%
EPS Next 5Y26.31%
Revenue Next Year-51.36%
Revenue Next 2Y-31.7%
Revenue Next 3Y-21.21%
Revenue Next 5Y-15.65%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
OCI.AS Yearly Revenue VS EstimatesOCI.AS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2B 4B 6B 8B
OCI.AS Yearly EPS VS EstimatesOCI.AS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 4 6

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for OCI. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 25.24 indicates a quite expensive valuation of OCI.
OCI's Price/Forward Earnings is on the same level as the industry average.
OCI's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 92.74.
Industry RankSector Rank
PE N/A
Fwd PE 25.24
OCI.AS Price Earnings VS Forward Price EarningsOCI.AS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

The rest of the industry has a similar Price/Free Cash Flow ratio as OCI.
Industry RankSector Rank
P/FCF 43.91
EV/EBITDA N/A
OCI.AS Per share dataOCI.AS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as OCI's earnings are expected to grow with 42.31% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y60.43%
EPS Next 3Y42.31%

More info and screens

0

5. Dividend

5.1 Amount

OCI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OCI NV

AMS:OCI (2/4/2025, 7:00:00 PM)

10.9

0 (0%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)11-12 2024-11-12
Earnings (Next)02-18 2025-02-18/amc
Inst Owners30.9%
Inst Owner ChangeN/A
Ins Owners8.71%
Ins Owner ChangeN/A
Market Cap2.30B
Analysts77.14
Price Target16.01 (46.88%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend4.68
Dividend Growth(5Y)N/A
DP-34.4%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)486.8%
Min EPS beat(2)232.01%
Max EPS beat(2)741.58%
EPS beat(4)2
Avg EPS beat(4)85.49%
Min EPS beat(4)-492.57%
Max EPS beat(4)741.58%
EPS beat(8)3
Avg EPS beat(8)31.49%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)37.56%
Min Revenue beat(2)20.15%
Max Revenue beat(2)54.98%
Revenue beat(4)2
Avg Revenue beat(4)8.41%
Min Revenue beat(4)-23.05%
Max Revenue beat(4)54.98%
Revenue beat(8)5
Avg Revenue beat(8)21.58%
Revenue beat(12)9
Avg Revenue beat(12)32.19%
Revenue beat(16)12
Avg Revenue beat(16)36.43%
PT rev (1m)-0.44%
PT rev (3m)-46.99%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-515.32%
EPS NY rev (3m)-515.32%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-4.05%
Revenue NY rev (3m)-4.05%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 25.24
P/S 0.59
P/FCF 43.91
P/OCF 4.28
P/B 2.57
P/tB 2.73
EV/EBITDA N/A
EPS(TTM)-0.47
EYN/A
EPS(NY)0.43
Fwd EY3.96%
FCF(TTM)0.25
FCFY2.28%
OCF(TTM)2.55
OCFY23.36%
SpS18.6
BVpS4.24
TBVpS4
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -5.57%
ROE -54.32%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 2.1%
FCFM 1.33%
ROA(3y)4.7%
ROA(5y)1.72%
ROE(3y)13.16%
ROE(5y)-0.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 2.03
Debt/FCF 44.53
Debt/EBITDA N/A
Cap/Depr -4159.17%
Cap/Sales 12.36%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.39
Quick Ratio 1.37
Altman-Z 0.2
F-Score4
WACC5.65%
ROIC/WACCN/A
Cap/Depr(3y)123.26%
Cap/Depr(5y)93.86%
Cap/Sales(3y)13.94%
Cap/Sales(5y)11.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-123.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%164.52%
EPS Next Y91.45%
EPS Next 2Y60.43%
EPS Next 3Y42.31%
EPS Next 5Y26.31%
Revenue 1Y (TTM)-63.19%
Revenue growth 3Y-17.33%
Revenue growth 5Y-9.61%
Sales Q2Q%-11.72%
Revenue Next Year-51.36%
Revenue Next 2Y-31.7%
Revenue Next 3Y-21.21%
Revenue Next 5Y-15.65%
EBIT growth 1Y-116.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-2.37%
EBIT Next 3Y6.31%
EBIT Next 5Y-0.48%
FCF growth 1Y-98.26%
FCF growth 3Y-23.28%
FCF growth 5Y-15.81%
OCF growth 1Y-83.68%
OCF growth 3Y4.02%
OCF growth 5Y0.7%